This invention relates to compounds of the formula ##STR00001## wherein X is N and Y is S or O; or X is S or O and Y is N; R.sup.1 is hydrogen or C.sub.1-7-alkyl; R.sup.2 and R.sup.3 independently from each other are selected from the group consisting of hydrogen, C.sub.1-7-alkyl and C.sub.1-7-alkoxy; R.sup.4, R.sup.5, R.sup.6, and R.sup.7 independently from each other are selected from the group consisting of hydrogen, C.sub.1-7-alkyl, C.sub.3-7-cycloalkyl, halogen, C.sub.1-7-alkoxy, C.sub.1-7-alkyl-C.sub.1-7-alkoxy-C.sub.1-7-alkyl, C.sub.2-7-alkenyl, C.sub.2-7-alkinyl, fluoro-C.sub.1-7-alkyl and cyano; R.sup.8 is selected from the group consisting of hydrogen, C.sub.1-7-alkyl, C.sub.3-7-cycloalkyl and fluoro-C.sub.1-7-alkyl; R.sup.9 is selected from the group consisting of hydrogen, C.sub.1-7-alkyl, C.sub.2-7-alkinyl, C.sub.3-7-cycloalkyl and fluoro-C.sub.1-7-alkyl; R.sup.10 is selected from the group consisting of hydrogen, C.sub.1-7-alkyl, C.sub.2-7-alkinyl, C.sub.3-7-cycloalkyl and fluoro-C.sub.1-7-alkyl; R.sup.11 is aryl or heteroaryl; N is 0, 1 or 2; and all enantiomers and pharmaceutically acceptable salts and/or esters thereof and their use as PPAR activators.

 
Web www.patentalert.com

< Methods of using thiazolidine derivatives to treat cancer or inflammation

> 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

~ 00419